



Comisión Nacional del Mercado de Valores
Att. Director del Área de Mercados
c/ Edison núm. 4
28006 Madrid

Madrid, September 27, 2022

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

At its meeting today, the Board of Directors of Pharma Mar, S.A. (“**Pharma Mar**” or the “**Company**”) decided to cease its diagnostics activity, which it is carried out through its wholly-owned subsidiary Genomica, S.A.U. (hereinafter, “**Genomica**”).

This decision is part of the Company's strategy to focus on its core business of developing and marketing drugs.

Genomica's core business is molecular diagnostics, mainly the development and commercialization of diagnostic kits. Genomica closed last financial year 2021 with a negative operating and investment cash consumption of EUR 3.2 million, a turnover of EUR 5.2 million and a net loss of EUR 3.2 million. These losses reduced the consolidated operating margin by 4%.

Given the significant investment that would be necessary to grow this business segment in an environment of falling prices and margins in the sector, Pharma Mar's Board of Directors, after evaluating various alternatives, decided to discontinue this business segment, which is not strategic for the group. Accordingly, the Board of Directors of Pharma Mar has agreed to initiate the corresponding procedures for the dissolution and liquidation of its subsidiary Genomica, S.A.U., subject to the legally or conventionally applicable procedures for negotiation with the employees.